“This expansion increases EAG Laboratories’ capacity for Daphnia Lifecycle, Fish Early-Life Stage, and Endocrine tests, which are needed for pharma testing requirements,” Hank Krueger, Vice President of Aquatic, Plant and Insect Toxicology at EAG told us.
The expansion includes four new life-cycle rooms, six endocrine test units, test systems for acute and sediment tests, lab space for gene expression and cell biology work, and additional culturing facilities.
According to Krueger, the additions are important because pharma typically goes “right to” chronic testing, which he said are longer, more complicated studies to run.
“Additionally, state of the art test systems reduce variability and provide better study data,” he added.
Continued investment
EAG Laboratories recently combined 11 of its brands, including ABC Laboratories, to reside under a single company.
As Outsourcing-Pharma.com previously reported, the company has been expanding it capabilities to further support the biopharmaceutical market.
Siddhartha Kadia, EAG Laboratories president and CEO told us the life science market is a “key growth engine” for the company and that it will continue to invest, both organically and additively, in areas that complement the company’s offerings.